BN
|
BusinessAI Desk•1 views

Generic Semaglutide Surge in India Sparks Price War as Novo Nordisk Defends Market Share

Following the expiration of Novo Nordisk's patent in India, multiple local companies launched generic semaglutide at prices up to 80% lower, sparking a price war in a market with 100 million diabetics. Novo responded with price cuts and partnerships to defend its share, but faces potential global revenue declines of 5-13% in 2026 due to patent expirations. Indian generics grapple with complex manufacturing and quality control issues, while concerns arise about exports to protected markets. The competition highlights the tension between affordability and brand loyalty in the GLP-1 drug sector.

Ad slot
Generic Semaglutide Surge in India Sparks Price War as Novo Nordisk Defends Market Share

India has seen the launch of affordable generic semaglutide drugs from multiple domestic pharmaceutical companies following the expiration of Novo Nordisk's patent, triggering intense price competition in a key global market.

First Wave of Generic Launches

  • At least five Indian drugmakers, including Sun Pharma, Dr. Reddy's, Natco, and Alkem, have introduced generic semaglutide since August 9, 2025.
  • Prices are significantly lower: Sun Pharma offers a weekly injection for as low as 750 rupees ($8), compared to Novo's 8,800-10,000 rupees, representing up to an 80% discount.
  • Dr. Reddy's launched semaglutide for diabetes at around 4,200 rupees per month and targets annual sales of 12 million pens globally.
  • Natco Pharma and Alkem Laboratories provide even steeper discounts, with monthly prices starting at 1,250 and 1,800 rupees, respectively.

Novo Nordisk's Counterstrategies

  • Novo Nordisk preemptively cut the price of its obesity drug Wegovy by 37% in India before the patent expiry.
  • The company has formed partnerships with Emcure Pharma and Abbott India to market its drugs under new brand names—Poviztra and Extensior—to enhance distribution reach.
  • Vikrant Shrotriya, managing director of Novo Nordisk India, emphasized that the company's ecosystem and technology justify its pricing despite reductions.
Ad slot

India's High-Stakes Healthcare Market

  • India hosts around 100 million people with diabetes and a high obesity rate, making it a critical market for GLP-1 drugs.
  • The nation's generic drug industry supplies approximately 20% of global off-patent medicines, earning it the title "the world's pharmacy."
  • GLP-1 drug sales in India surged 178% year-on-year to 14.46 billion rupees by February 2025, per Pharmarack data.

Manufacturing and Quality Control Hurdles

  • Semaglutide is a peptide-based drug requiring specialized production, cold chain storage, and stringent quality controls, unlike simpler generics.
  • Experts note that quality control for such complex molecules is challenging, with no room for contaminants or side products.
  • Indian manufacturers are improving compliance, but standards are still evolving compared to Europe or the U.S., according to industry analysts.

Global Revenue Impact and Export Concerns

  • Patent expirations in India, Canada, Brazil, and China this year could reduce Novo Nordisk's global revenue by 5-13% in 2026, as forecasted by the company.
  • Analysts warn that Indian generics might be diverted to patent-protected markets, though adherence to laws could help Novo maintain dominance.
  • Brand reputation remains a key defense for Novo, with consultants noting that its premium image acts as a "moat" against cheaper alternatives.
Ad slot